Paradoxical association of lipoprotein measures with incident atrial fibrillation

Circulation: Arrhythmia and Electrophysiology

Volumn 7, Issue 4, 2014, Pages 612-619

  Mora, Samia ^a   Akinkuolie, Akintunde O ^a   Sandhu, Roopinder K ^b   Conen, David ^c   Albert, Christine M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Apolipoproteins; Atrial fibrillation; Lipids; Primary prevention

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; LIPID;

ADULT; AGE; ARTICLE; ASSOCIATION; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; IMMUNOASSAY; LIPOPROTEIN BLOOD LEVEL; MIDDLE AGED; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; AGED; BLOOD; CONTROLLED CLINICAL TRIAL; INCIDENCE; PARTICLE SIZE; PREDICTIVE VALUE; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; UNITED STATES;

APOLIPOPROTEINS; ATRIAL FIBRILLATION; LIPIDS; PRIMARY PREVENTION;

AGED; APOLIPOPROTEINS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BOSTON; CHOLESTEROL, LDL; FEMALE; HUMANS; IMMUNOASSAY; INCIDENCE; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PARTICLE SIZE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 84907877192     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.113.001378     Document Type: Article

References (35)

1. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG. Prevention of atrial fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop. Circulation. 2009;119:606-618.
2. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
3. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119:2146-2152.
4. Iguchi Y, Kimura K, Shibazaki K, Aoki J, Kobayashi K, Sakai K, Sakamoto Y. Annual incidence of atrial fibrillation and related factors in adults. Am J Cardiol. 2010;106:1129-1133.
5. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. Circ J. 2011;75:2767-2774.
6. Lopez FL, Agarwal SK, Maclehose RF, Soliman EZ, Sharrett AR, Huxley RR, Konety S, Ballantyne CM, Alonso A. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities Study. Circ Arrhythm Electrophysiol. 2012;5:155-162.
7. Goonasekara CL, Balse E, Hatem S, Steele DF, Fedida D. Cholesterol and cardiac arrhythmias. Expert Rev Cardiovasc Ther. 2010;8:965-979.
8. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26: 847-870.
9. Mathew ST, Patel J, Joseph S. Atrial fibrillation: mechanistic insights and treatment options. Eur J Intern Med. 2009;20:672-681.
10. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
11. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006;295:1412-1419.
12. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931-939.
13. Hainline A, Karon J, Lippel K. Manual of Laboratory Operations: Lipid Research Clinics Program and Lipid and Lipoprotein Analysis. Bethesda, MD: U.S. Dept of Health and Human Services; 1982.
14. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117:1255-1260.
15. Tanner RM, Baber U, Carson AP, Voeks J, Brown TM, Soliman EZ, Howard VJ, Muntner P. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2011;108:227-232.
16. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-1379.
17. Levitan I, Christian AE, Tulenko TN, Rothblat GH. Membrane cholesterol content modulates activation of volume-regulated anion current in bovine endothelial cells. J Gen Physiol. 2000;115:405-416.
18. Martens JR, Navarro-Polanco R, Coppock EA, Nishiyama A, Parshley L, Grobaski TD, Tamkun MM. Differential targeting of Shaker-like potassium channels to lipid rafts. J Biol Chem. 2000;275:7443-7446.
19. Abi-Char J, Maguy A, Coulombe A, Balse E, Ratajczak P, Samuel JL, Nattel S, Hatem SN. Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. J Physiol. 2007;582(Part 3):1205-1217.
20. Dart C. Lipid microdomains and the regulation of ion channel function. J Physiol. 2010;588(Part 17):3169-3178.
21. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010;59:1153-1160.
22. Paynter NP, Sesso HD, Conen D, Otvos JD, Mora S. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem. 2011;57:1178-1187.
23. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N; Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172:799-809.
24. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, Faber J, Hansen PR, Pedersen OD, Torp-Pedersen C, Gislason GH. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345:e7895.
25. Wilcox HG, Heimberg M. Effects of hyperthyroidism on synthesis, secretion and metabolism of the VLDL apoproteins by the perfused rat liver. Biochim Biophys Acta. 1991;1081:246-252.
26. Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96:269-281.
27. Nielsen LB, Véniant M, Borén J, Raabe M, Wong JS, Tam C, Flynn L, Vanni-Reyes T, Gunn MD, Goldberg IJ, Hamilton RL, Young SG. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation. 1998;98:13-16.
28. Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, Goldberg IJ. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem. 2004;279:4204-4211.
29. Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology. 1999;92:21-27.
30. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A; ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54:2023-2031.
31. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;159:850-856.
32. Vyssoulis G, Karpanou E, Adamopoulos D, Kyvelou SM, Tzamou V, Michaelidis A, Stefanadis C. Metabolic syndrome and atrial fibrillation in patients with essential hypertension. Nutr Metab Cardiovasc Dis. 2013;23:109-114.
33. Díaz-Peromingo JA, Albán-Salgado A, García-Suárez F, Sánchez-Leira J, Saborido-Froján J, Iglesias-Gallego M. Lipoprotein(a) and lipid profile in patients with atrial fibrillation. Med Sci Monit. 2006;12:CR122-CR125.
34. Umetani K, Kodama Y, Nakamura T, Mende A, Kitta Y, Kawabata K, Obata JE, Takano H, Kugiyama K. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circ J. 2007;71:252-255.
35. Lopez FL, Huxley RR, Konety S, Alonso A, Agarwal SK, Maclehose RF, Soliman EZ, Sharrett AR, Ballantyne CM. Response to letter from Watanabe and Aizawa regarding article, "Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: The Atherosclerosis Risk in Communitites Study," by Lopez et al. Circ Arrhythm Electrophysiol. 2012;5:e81.